The Chase Group is pleased to continue partnership with Marinus in building their leadership team with the recent placement of the Vice President of Clinical Development and Pharmacovigilance. The successful candidate will be responsible for the medical leadership of the postpartum depression (PPD) programs and drug safety.
This executive’s experience in clinical development within the neuropsychiatric and CNS therapies will be instrumental as Marinus completes its Phase 2 trials in PPD and continues to develop its later-stage development strategy in depression.
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of ganaxolone, which offers a new mechanism of action, demonstrated efficacy and safety, and convenient dosing to improve the lives of patients suffering from epilepsy and neuropsychiatric disorders.
The Chase Group Places VP of Clinical Development and Pharmacovigilance at Marinus Pharmaceuticals
The Chase Group is pleased to continue partnership with Marinus in building their leadership team with the recent placement of the Vice President of Clinical Development and Pharmacovigilance. The successful candidate will be responsible for the medical leadership of the postpartum depression (PPD) programs and drug safety.
This executive’s experience in clinical development within the neuropsychiatric and CNS therapies will be instrumental as Marinus completes its Phase 2 trials in PPD and continues to develop its later-stage development strategy in depression.
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of ganaxolone, which offers a new mechanism of action, demonstrated efficacy and safety, and convenient dosing to improve the lives of patients suffering from epilepsy and neuropsychiatric disorders.- Categories: Life Sciences, Pharmaceutical
The Chase Group Makes Another Successful Placement at Eli Lilly
The Chase Group is pleased to continue our partnership with Eli Lilly in the successful placement of a new Senior Medical Advisor, Medical Affairs on…
Aeglea BioTherapeutics Builds Rare Disease Clinical Development Team Through Partnership with The Chase Group, Inc.
Through our ongoing partnership, Aeglea Biotherapeutics has secured a Vice President, Clinical Development, Rare Disease. The new Vice President will play a crucial role in…-
Eli Lilly Welcomes New Vice President, Immuno-Oncology Global & US Medical Affairs
The Chase Group is pleased to announce the placement of the Vice President, Immuno-Oncology Global & US Medical Affairs for Eli Lilly. The successful candidate… 
The Chase Group Places VP of Clinical Development and Pharmacovigilance at Marinus Pharmaceuticals
The Chase Group is pleased to continue partnership with Marinus in building their leadership team with the recent placement of the Vice President of Clinical…-
The Chase Group Secures the Vice President, US and Global Medical Affairs for Eli Lilly
The Chase Group is pleased to announce the successful completion of the Vice President, US and Global Medical Affairs at Eli Lilly. The new Vice… 
Ionis Pharmaceuticals Secures Associate Director, Investor Relations
The Chase Group is pleased to announce our latest placement for Ionis Pharmaceuticals. Due to exciting organizational growth, Ionis welcomes a new Associate Director, Investor…